Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition
Presentation Title: Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)
Session Title: Plenary Scientific Session
Session Date & Time:
Abstract Number: 2
Location: Georgia World Congress Center, Bldg C –
The accepted abstract is available online on the ASH website at http://www.hematology.org/Annual-Meeting/.
Conference Call and Webcast Information
Blueprint Medicines will host a conference call and webcast on Monday, December 11, 2017 at 6:00 a.m. ET to discuss the updated BLU-285 clinical data presented at ASH. To participate in the conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and refer to conference ID 4072589. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be available approximately two hours after the conference call and will be available for 30 days following the call.
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-updated-data-from-ongoing-phase-1-clinical-trial-of-blu-285-in-patients-with-advanced-systemic-mastocytosis-in-plenary-scientific-session-at-59th-ash-annual-meeting-and-exposition-300547305.html
Kristin Hodous, 617 714 6674, email@example.com; Jim Baker, 617 844 8236, firstname.lastname@example.org